Palvella Therapeutics, Inc. (FRA:PI6)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.61B +130.5% |
| Revenue (ttm) | n/a |
| Net Income | -54.00M |
| EPS | -4.37 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 300 |
| Open | 112.00 |
| Previous Close | 112.00 |
| Day's Range | 112.00 - 112.00 |
| 52-Week Range | 60.00 - 137.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 4, 2026 |
About Palvella Therapeutics
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin ... [Read more]
News
Clear Street sees positive read for Palvella from FDA rare disease framework
Noting that the FDA launched its Rare Disease Framework Initiative on October 14, Clear Street sees “meaningful positive readthrough” for Palvella Therapeutics (PVLA) as the framework’s stated princip...
Palvella Therapeutics Transcript: Chardan's 10th Annual Healthcare Conference
QTORIN rapamycin is progressing toward a potential H1 next-year FDA decision and commercial launch, with MLM and CVM representing an estimated $1 billion-$3 billion peak-sales opportunity. Additional trials and two disease-program announcements are planned by year-end.
Raymond James says new data supportive of broad label for Qtorin
Raymond James analyst Ryan Deschner keeps a Strong Buy rating on Palvella Therapeutics (PVLA) announced yesterday morning the presentations of two posters highlighting new pediatric subgroup analyses ...
Palvella Therapeutics initiated with an Outperform at William Blair
William Blair initiated coverage of Palvella Therapeutics (PVLA) with an Outperform rating. Palvella is a rare disease company that takes drugs already known to work and reformulates them with its…
Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference
Phase 3 SELVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and a Blinded Combined Score of Lesion Height, Vesicle Appearance, and Leaking/Bleeding
Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
WAYNE, Pa., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializi...
Palvella Therapeutics price target lowered to $246 from $270 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Palvella Therapeutics (PVLA) to $246 from $270 and keeps a Buy rating on the shares. The firm updated the company’s model to…
Palvella Therapeutics management to meet with Truist
Meeting to be held in Boston on October 6 hosted by Truist.
Palvella receives third year of grant funding from FDA for QTORIN
Palvella Therapeutics (PVLA) announced that the Company has received a third year of grant funding from the FDA Office of Orphan Products Development. The funding supports the Phase 3 SELVA…
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved
Palvella Therapeutics transferred with Buy rating at Chardan
Chardan kept a Buy rating on Palvella Therapeutics (PVLA) with a $240 price target following a transfer of coverage. Palvella is a late-stage rare disease company whose lead asset, Qtorin…
Palvella Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The company is advancing first-in-disease therapies for rare skin and vascular diseases, with its lead candidate QTORIN rapamycin under FDA review and a robust pipeline targeting multibillion-dollar markets. Strong clinical data, a proprietary platform, and a well-funded launch strategy position it for significant growth.
Palvella Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The company is advancing its QTORIN platform for rare skin and vascular diseases, with a lead NDA filed for microLM and anticipated FDA approval in 2027. Strong IP, regulatory exclusivity, and robust clinical data support high pricing and market adoption, while additional indications are progressing through late-stage development.
Palvella Therapeutics Appoints James R. Treat, M.D.
Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences
WAYNE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializ...
Palvella Therapeutics completes rolling submission of Qtorin NDA to FDA
Palvella Therapeutics (PVLA) announced that the company has completed the rolling submission of its new drug application, or NDA, to the FDA seeking approval of Qtorin 3.9% rapamycin anhydrous gel…
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pediatric and adult patients living with microcystic...
Palvella Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference
The company is advancing a robust pipeline of first-in-class therapies for rare skin and vascular diseases, highlighted by positive phase III data in mLM and a rolling NDA submission. Commercial launch preparations are well underway, supported by strong leadership, a $251 million cash position, and plans for further pipeline and geographic expansion.
Palvella Therapeutics price target lowered to $207 from $210 at Truist
Truist lowered the firm’s price target on Palvella Therapeutics (PVLA) to $207 from $210 and keeps a Buy rating on the shares.
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializi...
Palvella Therapeutics price target raised to $232 from $227 at Canaccord
Canaccord raised the firm’s price target on Palvella Therapeutics (PVLA) to $232 from $227 and keeps a Buy rating on the shares. The firm updated its model following Q2 results…
Palvella Therapeutics reports Q2 EPS ($1.52), consensus ($1.15)
“We made significant progress during the second quarter, completing our pre-NDA meeting with FDA and initiating the rolling NDA submission for QTORIN rapamycin in microcystic lymphatic malformations,”...
Palvella Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw major milestones, including positive phase III results for QTORIN rapamycin in mLM, rolling NDA submission, and a $230M capital raise. The company is well-funded for launch and pipeline expansion, with multiple rare disease programs advancing and strong physician and payer interest.
Palvella Therapeutics Earnings release: Q2 2026
Palvella Therapeutics released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Palvella Therapeutics Quarterly report: Q2 2026
Palvella Therapeutics has published its Q2 2026 quarterly earnings report on August 4, 2026.